A. Inbal et al., EVALUATION OF SOLVENT DETERGENT-TREATED PLASMA IN THE MANAGEMENT OF PATIENTS WITH HEREDITARY AND ACQUIRED COAGULATION DISORDERS, Blood coagulation & fibrinolysis, 4(4), 1993, pp. 599-604
Haemostatic efficacy and pharmacokinetic analysis of solvent/detergent
(S/D) treated, virus inactivated plasma (Octaplas(TM), Germany) was e
valuated in eight patients with hereditary factor VII, X and XI defici
ency and in three patients with acquired coagulation disorders due to
liver disease. The patients received the S/D plasma for treatment of h
aemarthrosis, menorrhagia or before surgical procedures. In all the pa
tients the S/D plasma was sufficient to prevent or stop bleeding. Side
effects included urticaria (one patient) and moderate anaphylactoid r
eaction (one patient). No evidence of plasma-born viral infections was
observed up to 12 months after the treatment (95% confidence limits 0
-22%). Calculated mean half-life of coagulation factors VII, X and XI
was 4.36 h, 49.21 h and 44.5 h, respectively, similar to that observed
with fresh-frozen plasma. Because of retained coagulation factor inte
grity and improved viral safety, S/D plasma could be considered a supe
rior alternative to standard fresh-frozen plasma.